Grants.gov · NIH · Grant
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
National Institutes of Health
- Status
- Open
- Maximum funding
- $150K
- Deadline
- Aug 11, 2027
- Instrument
- Grant
About this funding opportunity
The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.
Topic areas: Education and Training, Life Sciences and Health.
Funding amount
This grant provides Up to $150K in funding, up to $150K per award.
Deadline
Applications are due Aug 11, 2027. Confirm the exact closing time on the official program page before applying.
Who can apply
This opportunity is open to the following applicant types:
- Public Authorities
- Other
- SME
- Large Company
- University
- NGOs
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs); U.S. Territory or Possession.
Agency
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) is administered by National Institutes of Health (NIH), listed via Grants.gov.
Open the official opportunity page Browse all US R&D funding on GrantField
Programme data is aggregated by GrantField from public sources and may change. Always verify details on the official page before applying.